Head-To-Head Survey: CV Sciences (OTCMKTS:CVSI) versus Aurinia Pharmaceuticals (NASDAQ:AUPH)
by Amy Steele · The Cerbat GemCV Sciences (OTCMKTS:CVSI – Get Free Report) and Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, dividends, profitability, risk and institutional ownership.
Volatility and Risk
CV Sciences has a beta of 0.42, indicating that its share price is 58% less volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500.
Profitability
This table compares CV Sciences and Aurinia Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CV Sciences | -11.15% | -94.61% | -20.85% |
| Aurinia Pharmaceuticals | 99.97% | 26.62% | 19.65% |
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for CV Sciences and Aurinia Pharmaceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CV Sciences | 0 | 0 | 0 | 0 | 0.00 |
| Aurinia Pharmaceuticals | 0 | 4 | 2 | 0 | 2.33 |
Aurinia Pharmaceuticals has a consensus target price of $17.25, suggesting a potential upside of 8.90%. Given Aurinia Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Aurinia Pharmaceuticals is more favorable than CV Sciences.
Valuation & Earnings
This table compares CV Sciences and Aurinia Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CV Sciences | $13.79 million | 0.43 | -$960,000.00 | N/A | N/A |
| Aurinia Pharmaceuticals | $298.30 million | 6.83 | $287.20 million | $2.17 | 7.30 |
Aurinia Pharmaceuticals has higher revenue and earnings than CV Sciences.
Insider & Institutional Ownership
36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. 6.7% of CV Sciences shares are owned by insiders. Comparatively, 12.2% of Aurinia Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
Aurinia Pharmaceuticals beats CV Sciences on 12 of the 12 factors compared between the two stocks.
About CV Sciences
CV Sciences, Inc. develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol (CBD) in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The company offers its products under the PlusCBD, ProCBD, HappyLane, CVAcute, CVDefense, and PlusCBD Pet brands in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, elect distributors, brick and mortar retailers, and select e-tailers. It is also developing cannabinoids intended to treat medical indications, including CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.